Comprehensive Pneumology Center, Ludwig Maximilians University Hospital, Member of the German Center for Lung Research (DZL), and Helmholtz Zentrum München, Munich, Germany.
Research Unit Analytical BioGeoChemistry (BGC), Helmholtz Zentrum München, Oberschleissheim, Germany.
J Allergy Clin Immunol. 2017 May;139(5):1525-1535. doi: 10.1016/j.jaci.2016.09.003. Epub 2016 Sep 23.
Chronic immune diseases, such as asthma, are highly prevalent. Currently available pharmaceuticals improve symptoms but cannot cure the disease. This prompted demands for alternatives to pharmaceuticals, such as probiotics, for the prevention of allergic disease. However, clinical trials have produced inconsistent results. This is at least partly explained by the highly complex crosstalk among probiotic bacteria, the host's microbiota, and immune cells. The identification of a bioactive substance from probiotic bacteria could circumvent this difficulty.
We sought to identify and characterize a bioactive probiotic metabolite for potential prevention of allergic airway disease.
Probiotic supernatants were screened for their ability to concordantly decrease the constitutive CCL17 secretion of a human Hodgkin lymphoma cell line and prevent upregulation of costimulatory molecules of LPS-stimulated human dendritic cells.
Supernatants from 13 of 37 tested probiotic strains showed immunoactivity. Bioassay-guided chromatographic fractionation of 2 supernatants according to polarity, followed by total ion chromatography and mass spectrometry, yielded CHNO as the molecular formula of a bioactive substance. Proton nuclear magnetic resonance and enantiomeric separation identified D-tryptophan. In contrast, L-tryptophan and 11 other D-amino acids were inactive. Feeding D-tryptophan to mice before experimental asthma induction increased numbers of lung and gut regulatory T cells, decreased lung T2 responses, and ameliorated allergic airway inflammation and hyperresponsiveness. Allergic airway inflammation reduced gut microbial diversity, which was increased by D-tryptophan.
D-tryptophan is a newly identified product from probiotic bacteria. Our findings support the concept that defined bacterial products can be exploited in novel preventative strategies for chronic immune diseases.
慢性免疫性疾病(如哮喘)的发病率很高。目前可用的药物可改善症状,但无法治愈疾病。这促使人们寻求替代药物的方法,例如益生菌,以预防过敏性疾病。然而,临床试验的结果并不一致。这至少部分是由于益生菌、宿主微生物群和免疫细胞之间高度复杂的串扰所解释的。从益生菌中鉴定出一种生物活性物质可以避免这种困难。
我们试图鉴定和表征一种益生菌代谢产物,用于预防过敏性气道疾病。
筛选益生菌上清液,以确定其是否具有降低人霍奇金淋巴瘤细胞系组成性 CCL17 分泌和预防 LPS 刺激的人树突状细胞共刺激分子上调的能力。
在 37 株测试的益生菌菌株中,有 13 株的上清液具有免疫活性。根据极性对 2 种上清液进行生物活性导向的色谱分离,然后进行总离子色谱和质谱分析,得到 CHNO 作为生物活性物质的分子式。质子核磁共振和对映体分离鉴定出 D-色氨酸。相比之下,L-色氨酸和其他 11 种 D-氨基酸没有活性。在实验性哮喘诱导前给小鼠喂食 D-色氨酸可增加肺部和肠道调节性 T 细胞的数量,减少肺部 T2 反应,并改善过敏性气道炎症和高反应性。过敏性气道炎症降低了肠道微生物多样性,而 D-色氨酸增加了肠道微生物多样性。
D-色氨酸是一种从益生菌细菌中鉴定出的新型产物。我们的研究结果支持这样的概念,即可以利用特定的细菌产物开发针对慢性免疫性疾病的新型预防策略。